ZNF430

Across TCGA pan-cancer cohorts, ZNF430 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF430 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZNF430 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF430 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, LIHC, and UCEC are the cancer types where ZNF430 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.063	0.688	<.001	30	view →
LIHC	DFS	Median	All	0.081	0.544	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
SKCM	DFS	Median	All	0.857	0.600	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNF430–BLCA (OS)

Open the BLCA breakdown →